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Abstract
This study investigated the impact of ACTAZIN™ green (2400 and 600 mg) and Livaux™ (2400 mg) gold kiwifruit supplements on faecal microbial
composition and metabolites in healthy and functionally constipated (FC) participants. The participants were recruited into the healthy group (n 20;
one of whom did not complete the study) and the FC group (n 9), each of whom consumed all the treatments and a placebo (isomalt) for 4 weeks in
a randomised cross-over design interspersed with 2-week washout periods. Modiﬁcation of faecal microbiota composition and metabolism was determined
by 16S rRNA gene sequencing and GC, and colonic pH was calculated using SmartPill® wireless motility capsules. A total of thirty-two taxa were measured
at greater than 1 % abundance in at least one sample, ten of which differed signiﬁcantly between the baseline healthy and FC groups. Speciﬁcally,
Bacteroidales and Roseburia spp. were signiﬁcantly more abundant (P< 0·05) in the healthy group and taxa including Ruminococcaceae, Dorea spp. and
Akkermansia spp. were signiﬁcantly more abundant (P< 0·05) in the FC group. In the FC group, Faecalibacterium prausnitzii abundance signiﬁcantly increased
(P= 0·024) from 3·4 to 7·0 % following Livaux™ supplementation, with eight of the nine participants showing a net increase. Lower proportions of F.
prausnitzii are often associated with gastrointestinal disorders. The discovery that Livaux™ supplementation increased F. prausnitzii abundance offers a
potential strategy for improving gut microbiota composition, as F. prausnitzii is a butyrate producer and has also been shown to exert anti-inﬂammatory
effects in many studies.
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The gastrointestinal tract harbours approximately 1014microbial
cells, consisting of over 1000 species or phylotypes, the majority
ofwhich reside in the colon(1,2). The colonicmicrobiota has been
associated with a wide range of health beneﬁts including
improved immune function and maturation, modiﬁed behav-
iour, regulation of satiety, inhibition of pathogens and augmen-
tation of mineral absorption(3–5). Imbalances in microbial
community composition may be caused by diet, genetics, age,
stress or xenobiotics and can induce a state of dysbiosis that
may promote a more disease-susceptible microbiota.
Consumption of certain types of dietary components can have
a major inﬂuence on the communities of colonic micro-
organisms, with changes typically being observed within 24 h
of consumption(6,7).
Abbreviations: FC, functionally constipated; H, high dose; L, low dose.
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Kiwifruit has been implicated in promoting several aspects
of gut health including improving stool frequency, increasing
commensal bacteria and improving aspects of immune func-
tion(8–10). These beneﬁts are thought to derive from the inher-
ent levels of digestion-resistant carbohydrates, polyphenols
and vitamin C(11). The laxative effect of kiwifruit is undoubt-
edly the most well-studied health impact, whereas prebiotic
effects are less well understood. In addition to host absorption
of nutrients, enhancement of colonic microbial composition is
thought to mediate many of the beneﬁcial health effects of
kiwifruit. Organic acids such as acetate, propionate and butyr-
ate are produced as a result of microbial fermentation of kiwi-
fruit digestion-resistant carbohydrates(9). Organic acids may be
absorbed by colonocytes into the bloodstream where they are
further metabolised in the liver, muscle and other peripheral
tissues, and are associated with the mediation of immune effects,
cholesterol, satiety, and improved mineral absorption(12–14).
As the importance of a robust and diverse colonic micro-
biota is increasingly apparent and the potential of kiwifruit
to modulate the microbiota is being unearthed, a human inter-
vention study was conducted to ascertain the effect of
kiwifruit-derived supplements on colonic microbial compos-
ition and metabolism. Two kiwifruit-derived supplements,
ACTAZIN™ green-ﬂeshed (Actinidia chinensis var. deliciosa
‘Hayward’) and Livaux™ gold-ﬂeshed (Actinidia chinensis var.
chinensis ‘Zesy002’) (Anagenix Ltd), were used as dietary inter-
ventions in the trial. These capsules are cold-processed dietary
supplements, from which the skin and seeds are removed, for-
mulated to maintain the integrity of innate kiwifruit com-
pounds. The objective of this study was to assess the impact
of ACTAZIN™ and Livaux™ on the composition of colonic
bacteria, metabolites and gut pH, which was measured by 16S
rRNA gene sequencing, organic acid analysis and SmartPill®
technology, respectively.
Materials and methods
Study protocol
The study design was a randomised double-blind placebo-
controlled cross-over trial with participants consuming four dif-
ferent interventions for 4 weeks each, with a 2-week washout
between each intervention. A schematic view of the trial design
is shown in Supplementary Fig. S1. The interventions were
delivered in 4 × 600 mg capsules supplied by Anagenix Ltd pre-
pared to look identical to preserve intervention blinding
(Table 1). Detailed information on ingredient composition,
trial recruitment and participant inclusion and exclusion criteria
can be found in the Ansell et al.(15) paper reporting laxation end-
points of this trial. Brieﬂy, participants consumed four different
intervention combinations: placebo (isomalt coloured green)
(2400 mg/d), ACTAZIN™ L (600 mg/d), ACTAZIN™ H
(2400 mg/d) and Livaux™ (2400 mg/d) for 28 d each
intervention, with a 14 d washout period between each treat-
ment phase. ACTAZIN™ L (low dose, green kiwifruit) and
ACTAZIN™ H (high dose, green kiwifruit) were formulated
from cold-processed Actinidia chinensis var. deliciosa ‘Hayward’
green kiwifruit and Livaux™ was formulated from cold-
processed Actinidia chinensis var. chinensis ‘Zesy002’ gold-ﬂeshed
kiwifruit. The placebo ingredient was isomalt (1-O-α-D-
glucopyranosyl-D-mannitol). Subjects were asked to exclude
high-ﬁbre dietary supplements such as Metamucil, Beneﬁbre
and Phloe as well as maintaining their habitual dietary intakes
and physical activity habits and to refrain from eating fresh
kiwifruit for the study period. At the beginning and end of
each 4-week intervention period, participants were asked to
provide a faecal sample. The washout period of 2 weeks was
chosen to allow sufﬁcient time to return bowel habits to base-
line for the parameters measured (microbial ecology, microbial
metabolites and SmartPill® pH measurements). This study was
conducted according to the guidelines laid down in the
Declaration of Helsinki and all procedures involving human
subjects/patients were approved by the New Zealand Human
Disability and Ethics Committee (application number 12/
STH/72/AM01). Written informed consent was obtained
from all subjects/patients. The trial was registered with the
Australia New Zealand Clinical Trials Registry (registration num-
ber ACTRN: 12612001270808) (http://www.anzctr.org.au/).
DNA extraction and 16S rRNA gene sequencing
All faecal samples were collected and stored at −20°C until
analysis. Each sample (250 mg) was weighed into a sterile
microtube and DNA extracted using the MO-BIO
PowerSoil® DNA Isolation Kit (catalogue no. 12888;
MO-BIO Laboratories). Illumina MiSeq 16S rRNA gene
sequencing was performed as described in a previous study(16).
Bioinformatics
Quantitative Insights Into Microbial Ecology (QIIME) soft-
ware version 1.8.0 was used to analyse the Illumina MiSeq
sequencing data(17). To assemble paired-end reads into a single
continuous sequence, PANDASeq was used with parameters
of at least 40 bp overlap, a minimum of 350 bp length and
maximum of 500 bp length(18). Putative chimeras were ﬁltered
from the sequences and the reads clustered into operational
taxonomic units based on a 97 % identity threshold value
using USEARCH and UCLUST(19). A subsample of the
Table 1. Description of intervention composition
Intervention Treatment Dose (mg) Delivery – capsules/d
ACTAZIN™ L Green kiwifruit powder 600 1 × ACTAZIN™ + 3 × placebo
ACTAZIN™ H Green kiwifruit powder 2400 4 × ACTAZIN™
Livaux™ Gold kiwifruit powder 2400 4 × Livaux™
Placebo Isomalt coloured green (E102, E142) 2400 4 × placebo
L, low dose; H, high dose.
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total reads was taken to allow faster processing of the samples
and to normalise at approximately 15 000 reads per sample,
which is sufﬁcient for phylogenetic and taxonomic assign-
ment(20,21). Alignment of the sequences was carried out
using PyNAST(22) with reference to the Greengenes core ref-
erence database (version 13_8)(23). Taxonomic assignment was
made using the Ribosomal Database Project (RDP) naive
Bayesian classiﬁer(24). Healthy and functionally constipated
(FC) groups were analysed separately and the effect of each
of the four treatments on microbial community composition
determined by comparing the average abundance of each bac-
terial genus following treatment (greater than 1 % abundance
in at least one of the eight samples) with the average value
before intervention.
Organic acid quantification by GC
A 500–1000 mg portion of each faecal sample was weighed into a
clean tube and diluted 1:10 in PBS. An internal standard (ethyl
butyrate) was included to give a ﬁnal concentration of 5 mM.
Organic acids were quantiﬁed byGC using amodiﬁedmethod(25).
Analysis was performed on a Shimadzu GC system (GC-17A)
equipped with a ﬂame ionisation detector and ﬁtted with an
HP-1 column (Agilent Technologies). The instrument was con-
trolled and chromatograms acquired using GC Solution
Chromatography Data System software (Shimadzu, version 2.3).
Organic acid concentrations were expressed as μmol/g faeces.
SmartPill®
SmartPill® is a single-use, ingestible capsule and used in clin-
ical medicine as an alternative approach for determining
gastrointestinal transit time(26) instead of using radio-opaque
markers and scintigraphy. SmartPill® is able to measure in
situ gastrointestinal pH, pressure and temperature and uses tel-
emetry to relay information wirelessly to a small receiving
device worn during the study. Six participants from the FC
group underwent SmartPill® testing whilst on either the pla-
cebo or ACTAZIN™ H treatments. SmartPill® data were
compared between treatments to ascertain whether ingestion
of ACTAZIN™ H capsules had an impact on pH.
Migration of the SmartPill® capsule past the ileocaecal junction
into the proximal colon was characterised by a distinct decline
in pH. The entire colonic pH from the ileocaecal junction to
passing the capsule was averaged and compared between treat-
ments for all participants. Faecal samples originate from the
distal bowel, therefore distal rectosigmoid colon pH was deter-
mined by taking the last 35·4 % of total colonic pH measure-
ments as calculated in a study interpreting segmental colonic
transit times(27). Bacterial groups were correlated with distal
colonic pH data from SmartPill® measurements. A graphical
example of SmartPill® data output for a participant is shown
in Supplementary Fig. S2.
Statistical analysis
Statistical calculations were conducted in RStudio using the
statistics package(28). Bacterial groups were correlated with
rectosigmoid pH data from SmartPill® measurements using
the Spearman’s rank correlation calculation. The Wilcoxon
signed rank test was performed to assess signiﬁcant differ-
ences between taxa and signiﬁcant differences between organic
acid concentrations before and after each treatment. A P value
of less than 0·05 was deemed signiﬁcant after correcting for
multiple comparisons using the false discovery rate (FDR)
method in the p.adjust function in RStudio(29).
Results
16S rRNA gene sequencing
High-throughput sequencing of variable regions of the 16S
rRNA gene, ampliﬁed from faecal sample-derived bacterial
DNA, resulted in 26·3 million reads. After quality ﬁltering,
chimera removal and subsampling, a total of 3·72 million
reads were obtained at an average of 14 879 (14 139 mini-
mum–14 999 maximum) sequences per sample. Over all sam-
ples, 218 species-level phylotypes were observed at a 97 %
sequence identity threshold.
Analysis of the participants’ faecal microbiota composition
before intervention showed marked differences between the
healthy and FC cohorts. A total of thirty-two genera were mea-
sured at greater than 1 % abundance in at least one sample, ten
of which differed signiﬁcantly between the baseline healthy
and FC groups (Fig. 1). Furthermore, the ratio of Firmicutes
to Bacteroidetes differed between the groups at 2·25 and
3·19 for the healthy and FC groups, respectively. These num-
bers agree with other studies that show an increase in
Firmicutes in irritable bowel syndrome patients relative to
healthy controls(30).
In the healthy group, Clostridiales increased signiﬁcantly
after Livaux™ supplementation from 5·0 to 7·6 % (P =
0·042) (Table 2). In the FC group, Dorea spp. increased
from 0·9 to 1·4 % (P = 0·008) after the ACTAZIN™ H treat-
ment (Table 3). In the FC group, Faecalibacterium prausnitzii sig-
niﬁcantly increased after Livaux™ treatment from 3·4 to 7·0
% (P = 0·024), a two-fold increase as can be seen in
Table 3. Individual participant responses can be seen in
Supplementary Fig. S3, where eight out of the nine participants
exhibited a net increase in F. prausnitzii.
Organic acid production
Succinate signiﬁcantly decreased in concentration from 2·3 to
1·7 µmol/g (P= 0·040) following placebo treatment in the FC
group (Fig. 3). There were no other signiﬁcant alterations to
organic acid concentrations with any of the treatments.
Quantitative differences before and after each treatmentwere gen-
erally modest, except for acetate which increased or decreased by
up to 13 µmol/g after some treatments (Figs 2 and 3).
SmartPill®
SmartPill® data were used to determine the pH of the colonic
environment in a small group of participants taking the
ACTAZIN™ H capsules and the placebo treatment.
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Comparable pH values were observed between treatments, with
an average pH of 6·38 in the ACTAZINH treatment and an aver-
age pHof 6·30 in the placebo treatment (SupplementaryTable S4).
A Spearman rank correlation between bacterial groups and recto-
sigmoid pH provided two signiﬁcant values: Biﬁdobacterium spp.
negatively correlated with pH (−0·41; P= 0·044) and Coprococcus
spp. positively correlated with pH (0·43; P= 0·039).
Discussion
Other results arising from this trial, assessing laxation endpoints,
were published separately and showed that the kiwifruit supple-
ments were able to signiﬁcantly increase bowel movements in
healthy individuals(15). There is a strong relationship between
stool consistency and microbiota composition and diver-
sity(31,32), which is unsurprising as microbial metabolic end
Fig. 1. Boxplots displaying bacterial taxa in healthy (a) and functionally constipated (b) baseline samples of faecal microbiota that are present at greater than 1 %
abundance in at least one sample. The genera in bold font are significantly more abundant compared with the other group, as calculated by the Wilcoxon signed rank
test after false discovery rate correction for multiple comparisons (P ≤ 0·05). Ruminococcus_R, from Ruminococcaceae family; Ruminococcus_L, from
Lachnospiraceae family.
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Table 2. Relative abundance of prevalent bacterial groups in response to treatments in the healthy group†
Placebo Livaux™ ACTAZIN™ L ACTAZIN™ H
Pre Post Pre Post Pre Post Pre Post
Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM
Bacteroides 18·8 4·0 18·0 3·2 23·1 4·6 22·0 4·2 16·7 3·1 18·4 3·9 19·4 3·2 18·1 3·8
Ruminococcaceae‡ 16·3 2·4 19·6 3·0 17·4 2·3 17·8 2·5 19·9 2·5 22·2 3·8 18·4 2·6 19·9 3·3
Lachnospiraceae‡ 10·8 1·3 11·0 1·5 11·9 1·9 9·5 1·3 11·6 1·6 9·3 1·7 11·6 1·6 11·0 1·4
Faecalibacterium 7·0 1·5 5·7 1·0 7·2 1·6 5·3 0·9 6·3 1·6 4·6 0·8 6·7 1·1 6·5 1·6
Clostridiales‡ 5·9 0·9 5·7 1·0 5·0 0·9 7·6* 1·1 5·9 0·7 5·0 1·1 6·6 1·2 5·6 0·9
Coprococcus 6·6 1·0 5·5 0·8 5·9 1·1 5·1 0·7 5·4 0·8 5·2 0·8 5·1 0·8 4·9 0·8
Blautia 5·8 0·9 4·7 1·0 4·3 0·6 4·8 1·0 4·7 0·7 6·3 1·7 4·8 1·1 6·1 1·8
Ruminococcus_R 4·4 1·0 5·9 1·6 3·8 0·6 3·7 1·0 5·3 1·0 5·9 1·3 3·5 0·8 4·4 1·2
Rikenellaceae‡ 2·8 0·9 2·7 0·7 2·7 0·7 2·9 1·0 2·8 1·0 2·5 0·9 3·0 0·6 3·5 0·8
Bifidobacterium 3·0 1·0 2·3 0·6 2·5 1·2 2·1 0·6 2·0 0·4 3·5 1·1 2·7 0·9 2·6 0·8
Bacteroidales‡ 2·2 1·0 2·2 0·8 2·0 0·9 1·9 0·8 1·3 0·4 1·2 0·3 2·6 1·1 1·7 0·6
Lachnospira 1·6 0·5 1·1 0·2 1·3 0·3 1·5 0·5 1·0 0·2 1·1 0·3 1·8 0·5 1·3 0·4
Parabacteroides 1·2 0·3 1·6 0·5 1·8 0·6 1·1 0·2 1·3 0·3 1·0 0·2 1·7 0·3 1·5 0·3
Collinsella 1·8 0·7 1·2 0·4 0·9 0·4 1·3 0·4 1·6 0·6 1·2 0·3 1·5 0·6 1·1 0·3
Akkermansia 1·3 0·5 1·4 0·6 1·8 0·7 1·6 0·7 1·6 0·6 1·8 0·5 1·4 0·4 1·0 0·3
Oscillospira 1·1 0·2 1·1 0·2 1·1 0·2 1·6 0·3 1·4 0·2 1·5 0·5 1·2 0·1 1·5 0·2
Prevotella 1·5 0·7 2·6 1·8 0·8 0·4 2·1 1·5 2·5 1·33 0·7 0·3 0·9 0·5 1·6 0·9
Dorea 1·2 0·4 1·2 0·3 0·9 0·2 1·5 0·4 1·1 0·2 0·9 0·2 0·8 0·2 1·0 0·2
Clostridiaceae‡ 1·5 0·4 0·9 0·3 0·9 0·2 0·9 0·2 0·8 0·2 1·2 0·4 0·8 0·2 0·9 0·3
Unassigned 0·8 0·1 1·0 0·2 0·8 0·1 1·0 0·2 0·9 0·1 0·9 0·1 0·8 0·1 0·8 0·1
L, low dose; H, high dose; Ruminococcus_R, from Ruminococcaceae family.
* Significantly different compared with pre-treatment based on the Wilcoxon signed rank test after false discovery rate correction for multiple comparisons (P ≤ 0·05).
† Illumina MiSeq sequencing data displaying genera that are present at greater than 1 % abundance in at least one sample. Data are the calculated average values for all participants with their standard errors before and after each treatment period.
‡ Some bacteria could only be classified as far as the order or family level.
5
journals.cam
bridge.org/jns
Table 3. Relative abundance of prevalent bacterial groups in response to treatments in the functionally constipated group†
Placebo Livaux™ ACTAZIN™ L ACTAZIN™ H
Pre Post Pre Post Pre Post Pre Post
Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM
Ruminococcaceae‡ 17·2 2·3 19·9 2·9 17·1 3·8 16·3 2·1 17·9 2·6 15·0 2·3 16·5 3·1 18·8 2·1
Bacteroides 12·6 3·1 14·4 2·2 14·2 2·6 15·5 2·6 13·9 2·2 12·2 2·5 14·0 2·9 16·3 3·1
Lachnospiraceae‡ 11·4 1·6 8·0 2·3 10·0 2·5 13·9 3·3 10·8 3·1 11·0 2·3 11·7 2·5 8·7 2·2
Faecalibacterium 7·9 2·8 5·8 2·1 3·4 1·0 7·0* 1·1 4·9 1·7 5·0 1·4 7·7 2·1 3·1 1·0
Clostridiales‡ 4·8 0·6 6·8 1·7 6·4 1·3 5·5 1·1 6·4 1·2 6·7 1·7 6·0 1·4 7·5 1·8
Coprococcus 6·5 1·4 6·1 1·1 6·7 1·7 6·6 1·4 6·9 1·4 8·6 1·2 6·0 1·2 7·1 1·9
Blautia 6·6 1·8 3·5 0·9 7·1 2·0 6·0 1·5 6·9 1·5 7·5 1·8 5·9 2·1 5·4 1·3
Ruminococcus_R 9·4 2·6 5·1 1·0 5·7 1·4 4·9 0·7 5·5 2·0 6·7 1·5 5·1 1·1 6·6 1·3
Bifidobacterium 2·6 1·3 2·6 1·0 3·5 1·5 2·6 1·0 2·7 1·5 2·7 0·9 4·0 1·6 1·8 0·8
Akkermansia 2·7 1·7 4·8 2·0 5·0 1·8 2·6 1·0 3·3 1·1 3·3 1·5 3·6 1·0 5·6 2·3
Rikenellaceae‡ 2·3 0·6 3·1 0·6 3·9 1·2 2·4 0·5 4·0 1·1 3·9 1·3 2·6 0·7 3·2 0·9
Christensenellaceae‡ 1·0 0·6 1·5 0·6 2·2 1·4 1·1 0·6 1·8 0·8 1·4 0·6 2·3 1·6 2·2 1·3
Prevotella 1·8 1·1 0·6 0·3 0·2 0·1 0·5 0·3 0·5 0·3 0·9 0·5 2·0 1·1 0·2 0·1
Collinsella 1·6 0·6 1·2 0·3 1·6 0·4 1·3 0·3 1·2 0·4 1·8 0·7 1·6 0·6 1·4 0·3
Parabacteroides 1·3 0·4 1·3 0·4 1·2 0·3 1·3 0·4 1·7 0·4 1·2 0·4 1·3 0·4 1·5 0·3
Oscillospira 1·3 0·1 1·5 0·3 1·6 0·2 1·8 0·3 1·6 0·2 1·5 0·3 1·3 0·2 1·8 0·3
Lachnospira 1·0 0·5 1·0 0·4 0·6 0·2 1·6 0·9 1·3 0·5 1·2 0·5 1·3 0·6 0·5 0·1
Dorea 1·5 0·4 1·4 0·3 1·3 0·3 1·2 0·3 1·2 0·3 1·2 0·4 0·9 0·2 1·4* 0·3
Coriobacteriaceae‡ 0·9 0·3 1·2 0·5 1·5 0·4 1·2 0·5 1·1 0·3 1·1 0·3 0·8 0·2 1·2 0·4
Barnesiellaceae‡ 0·9 0·3 4·0 2·4 1·0 0·4 1·0 0·3 1·1 0·3 1·4 0·5 0·8 0·3 0·8 0·3
Clostridiaceae‡ 0·4 0·1 1·5 0·7 0·9 0·5 1·0 0·7 0·3 0·1 0·4 0·1 0·4 0·1 0·3 0·1
Unassigned 1·0 0·1 1·1 0·1 1·1 0·2 1·0 0·1 1·0 0·1 1·0 0·1 1·3 0·4 1·0 0·1
L, low dose; H, high dose; Ruminococcus_R, from Ruminococcaceae family.
* Significantly different compared with pre-treatment based on the Wilcoxon signed rank test after false discovery rate correction for multiple comparisons (P ≤ 0·05).
† Illumina MiSeq sequencing data displaying genera that are present at greater than 1 % abundance in at least one sample. Data are the calculated average values for all participants with their standard errors before and after each treatment period.
‡ Some bacteria could only be classified as far as the order or family level.
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products such as SCFA and gases can affect colonic transit
time(33,34). However, in this trial no correlations were observed
in those participants that exhibited an increase in stool frequency
and microbiota composition. Comparison between the baseline
microbiota composition of the healthy and FC groups has pro-
vided valuable insight to the bacterial aetiology of functional
constipation. Interesting ﬁndings between the cohorts were a
signiﬁcantly higher Bacteroidales abundance in healthy indivi-
duals and signiﬁcantly higher Akkermansia spp. abundance in
FC participants. Both patterns agree with a study assessing
microbiota composition and stool consistency(32).
In the present study, we found that several bacterial groups
were signiﬁcantly altered in abundance following kiwifruit sup-
plementation. Clostridiales increased by 2·6 % after Livaux™
supplementation in the healthy group, but as the order includes
a wide range of families and genera, including Lachnospiraceae,
Clostridiaceae, Ruminococcaceae, Veillonellaceae, etc. and
some pathogens, it is difﬁcult to draw meaningful conclusions
about the consequence of this increase. Dorea spp. increased
modestly after ACTAZIN H treatment in the FC group and
these members of the diverse Lachnospiraceae family are
major gas producers, mainly CO2 and H2
( 35).
A non-signiﬁcant decrease in F. prausnitzii from 7·2 to 5·3 %
was observed in the healthy group which could be due to already
high levels at baseline. Other studies have observed depleted F.
prausnitzii in irritable bowel syndrome patients compared with
healthy control subjects(30). It has been demonstrated that the
effect of baseline concentrations of a bacterial group may have
a substantial bearing on the magnitude of effect observed in
response to a dietary intervention(36,37). F. prausnitzii abundance
was signiﬁcantly elevated (3·6 %) in the FC group after a 4-week
period of supplementation with the gold kiwifruit-based
Livaux™. F. prausnitzii is one of the more populous species in
the human gastrointestinal tract, being typically observed at
over 5 % of the total proportion of the colonic microbiota of
healthy adults(38), in agreement with abundance data presented
in this study. Members of the Firmicutes phylum, F. prausnitzii
are commensal inhabitants of the human large bowel, with
demonstrated anti-inﬂammatory properties in vivo(39,40). One
study found thatF. prausnitziiwas able to utilise pectin and uronic
acids as substrates for growth and both are known constituents
of kiwifruit(41). Green and gold kiwifruit have been shown to
exhibit differences in digestibility, leading to altered soluble
and insoluble ﬁbre compositions reaching the large bowel(42),
Fig. 2. Organic acid concentrations in faecal samples in response to the four treatments in the healthy group as measured by GC, expressed in μmol/g faeces.
░, Pre-treatment; ■, after treatment; L, low dose; H, high dose. Values are means, with standard errors represented by vertical bars.
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which may be why differences were observed in the effect of
green and gold kiwifruit ﬁbre in this study. Low amounts of F.
prausnitzii have been associated with a range of intestinal disor-
ders including irritable bowel syndrome, atopy, diabetes and
inﬂammatory bowel diseases such as Crohn’s disease and ulcera-
tive colitis(30,39,40,43,44). These consistent observations show that
a depleted concentration of F. prausnitzii is an undesirable end-
point and therefore any treatment that can selectively stimulate
its proliferation in situ is likely to be a promising intervention
strategy.
The mechanisms by which F. prausnitzii facilitates its health-
promoting impact are most probably through butyrate produc-
tion and subsequent anti-inﬂammatory effects. Butyrate is the
preferred energy source for colonic epithelial cells and plays a
role in alleviating inﬂammation as well as mitigating carcino-
genesis, pathogenic colonisation and oxidative stress(12,45). A
mouse study by Sokol et al.(40) found that F. prausnitzii or F.
prausnitzii culture supernatant reduced the severity of
chemical-induced colitis, promoted the synthesis of anti-
inﬂammatory cytokines and mitigated pro-inﬂammatory cyto-
kine production, suggesting that anti-inﬂammatory effects are
mediated by secreted metabolites. Therefore, increasing the
amount of F. prausnitzii in the colon may help mitigate the
symptoms of gastrointestinal disorders, potentially through
elevated butyrate production.
There were minor differences between organic acids after
treatments which could be attributed to using faecal samples
as a proxy for in situ determination of organic acid compos-
ition and concentration. Organic acid concentrations decrease
distally in the large bowel due to a number of reasons includ-
ing secondary fermentation, absorption into the bloodstream
and/or utilisation of organic acids (particularly butyrate) by
colonocytes. Therefore, measurement of organic acids in faecal
samples would greatly underestimate the concentration of in
situ organic acids(46). Despite these limitations, butyrate was
slightly higher in faecal samples from participants after
Livaux™ treatment in the FC group, which aligns with the
increased F. prausnitzii abundance but it was not to a signiﬁcant
level.
It has been demonstrated that pH can alter microbial popu-
lations(47) and therefore it stands to reason that an altered pH
in the colon could modify the colonic microbial proﬁle. In the
present study, correlating pH with bacterial groups has
revealed one signiﬁcantly positive and one signiﬁcantly
Fig. 3. Organic acid concentrations in faecal samples in response to the four treatments in the functionally constipated group as measured by GC, expressed in μmol/
g faeces. ░, Pre-treatment; ■, after treatment; L, low dose; H, high dose. Values are means, with standard errors represented by vertical bars. * Significantly different
compared with pre-treatment based on the Wilcoxon signed rank test after false discovery rate correction for multiple comparisons (P ≤ 0·05).
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negative correlation. The discovery that Biﬁdobacterium spp.
abundance was signiﬁcantly higher at lower pH is an expected
result as it is an acid-producing bacterium, and hence tolerant
of such conditions. Increased biﬁdobacteria abundance is
positive because it is recognised as an established probiotic
genus, and in general a lower pH is seen as desirable as it
can exclude the growth of competing pathogens(48).
In conclusion, Livaux™ appears to stimulate proliferation
of the commensal F. prausnitzii in participants with low initial
F. prausnitzii concentrations and this may be associated with
higher in situ butyrate concentrations, although this is difﬁcult
to measure in a human study. These results bear clinical rele-
vance as stimulating an increase in an abundant butyrogenic
bacterium could have beneﬁcial consequences for ulcerative
colitis patients. Future work to corroborate these results
could entail in vitro studies to measure butyrate production
and F. prausnitzii stimulation in a closed system.
Supplementary material
The supplementary material for this article can be found at
https://doi.org/10.1017/jns.2017.52
Acknowledgements
We appreciate statistical review of this paper by Duncan
Hedderley. We acknowledge the technical assistance of
Nayer Ngametua and Genelle Healey with 16S rRNA gene
sequencing sample preparation. ACTAZIN™ and Livaux™
were provided by Anagenix Ltd.
This study was funded from the New Zealand Ministry of
Business, Innovation and Employment (Foods for Health at
Different Life Stages programme, contract C11X1312),
Anagenix Ltd and StratumNutrition (Saint Charles, MO, USA).
The authors have declared no conﬂict of interest.
References
1. Qin JJ, Li RQ, Raes J, et al. (2010) A human gut microbial gene
catalogue established by metagenomic sequencing. Nature 464,
59–65.
2. Rajilic-Stojanovic M & de Vos WM (2014) The ﬁrst 1000 cultured
species of the human gastrointestinal microbiota. FEMS Microbiol
Rev 38, 996–1047.
3. Bufﬁe CG & Pamer EG (2013) Microbiota-mediated colonization
resistance against intestinal pathogens.Nat Rev Immunol 13, 790–801.
4. Geurts L, Neyrinck AM, Delzenne NM, et al. (2014) Gut micro-
biota controls adipose tissue expansion, gut barrier and glucose
metabolism: novel insights into molecular targets and interventions
using prebiotics. Benef Microbes 5, 3–17.
5. Parnell JA & Reimer RA (2012) Prebiotic ﬁbres dose-dependently
increase satiety hormones and alter Bacteroidetes and Firmicutes in
lean and obese JCR:LA-cp rats. Br J Nutr 107, 601–613.
6. Walker AW, Ince J, Duncan SH, et al. (2011) Dominant and
diet-responsive groups of bacteria within the human colonic micro-
biota. ISME J 5, 220–230.
7. Wu GD, Chen J, Hoffmann C, et al. (2011) Linking long-term diet-
ary patterns with gut microbial enterotypes. Science 334, 105–108.
8. Bentley-Hewitt KL, Blatchford PA, Parkar SG, et al. (2012) Digested
and fermented green kiwifruit increases human β-defensin 1 and 2
production in vitro. Plant Foods Hum Nutr 67, 208–214.
9. Parkar SG, Rosendale D, Paturi G, et al. (2012) In vitro utilization of
gold and green kiwifruit oligosaccharides by human gut microbial
populations. Plant Foods Hum Nutr 67, 200–207.
10. Rush EC, Patel M, Plank LD, et al. (2002) Kiwifruit promotes laxa-
tion in the elderly. Asia Pac J Clin Nutr 11, 164–168.
11. Chan AO, Leung G, Tong T, et al. (2007) Increasing dietary ﬁber
intake in terms of kiwifruit improves constipation in Chinese
patients. World J Gastroenterol 13, 4771–4775.
12. HamerHM, JonkersD, VenemaK, et al. (2008) Review article: the role
of butyrate on colonic function. Aliment Pharmacol Ther 27, 104–119.
13. Saulnier DMA, Spinler JK, Gibson GR, et al. (2009) Mechanisms of
probiosis and prebiosis: considerations for enhanced functional
foods. Curr Opin Biotechnol 20, 135–141.
14. Wong JMW, de Souza R, Kendall CWC, et al. (2006) Colonic
health: fermentation and short chain fatty acids. J Clin
Gastroenterol 40, 235–243.
15. Ansell J, Butts CA, Paturi G, et al. (2015) Kiwifruit-derived supple-
ments increase stool frequency in healthy adults: a randomized,
double-blind, placebo-controlled study. Nutr Res 35, 401–408.
16. Blatchford P, Bentley-Hewitt KL, Stoklosinski H, et al. (2015) In
vitro characterisation of the fermentation proﬁle and prebiotic cap-
acity of gold-ﬂeshed kiwifruit. Benef Microbes 6, 829–839.
17. Caporaso JG, Kuczynski J, Stombaugh J, et al. (2010) QIIME
allows analysis of high-throughput community sequencing data.
Nat Methods 7, 335–336.
18. Masella AP, Bartram AK, Truszkowski JM, et al. (2012)
PANDAseq: paired-end assembler for illumina sequences. BMC
Bioinformatics 13, 31.
19. Edgar RC (2010) Search and clustering orders of magnitude faster
than BLAST. Bioinformatics 26, 2460–2461.
20. Caporaso JG, Lauber CL, Walters WA, et al. (2011) Global patterns
of 16S rRNA diversity at a depth of millions of sequences per sam-
ple. Proc Natl Acad Sci U S A 108, Suppl. 1, 4516–4522.
21. Schloss PD, Schubert AM, Zackular JP, et al. (2012) Stabilization of the
murine gut microbiome following weaning. Gut Microbes 3, 383–393.
22. Caporaso JG, Bittinger K, Bushman FD, et al. (2010) PyNAST: a
ﬂexible tool for aligning sequences to a template alignment.
Bioinformatics 26, 266–267.
23. DeSantis TZ, Hugenholtz P, Larsen N, et al. (2006) Greengenes, a
chimera-checked 16S rRNA gene database and workbench compat-
ible with ARB. Appl Environ Microbiol 72, 5069–5072.
24. Wang Q, Garrity GM, Tiedje JM, et al. (2007) Naive Bayesian clas-
siﬁer for rapid assignment of rRNA sequences into the new bacter-
ial taxonomy. Appl Environ Microbiol 73, 5261–5267.
25. Richardson AJ, Calder AG, Stewart CS, et al. (1989) Simultaneous
determination of volatile and non-volatile acidic fermentation pro-
ducts of anaerobes by capillary gas-chromatography. Lett Appl
Microbiol 9, 5–8.
26. TimmD,Willis H, ThomasW, et al. (2011) The use of a wirelessmotil-
ity device (SmartPill®) for the measurement of gastrointestinal transit
time after a dietary ﬁbre intervention. Br J Nutr 105, 1337–1342.
27. Metcalf AM, Phillips SF, Zinsmeister AR, et al. (1987) Simpliﬁed
assessment of segmental colonic transit. Gastroenterology 92, 40–47.
28. RStudio (2012) RStudio: integrated development environment for
R (version 0.97.551) [computer software]. Boston, MA. http://
www.rstudio.org/
29. Benjamini Y & Hochberg Y (1995) Controlling the false discovery
rate – a practical and powerful approach to multiple testing. J Royal
Stat Soc Series B Methodol 57, 289–300.
30. Rajilic-Stojanovic M, Biagi E, Heilig HG, et al. (2011) Global and
deep molecular analysis of microbiota signatures in fecal samples
from patients with irritable bowel syndrome. Gastroenterology 141,
1792–1801.
31. Gilbert JA & Alverdy J (2016) Stool consistency as a major con-
founding factor affecting microbiota composition: an ignored vari-
able? Gut 65, 1–2.
32. Vandeputte D, Falony G, Vieira-Silva S, et al. (2016) Stool consist-
ency is strongly associated with gut microbiota richness and com-
position, enterotypes and bacterial growth rates. Gut 65, 57–62.
9
journals.cambridge.org/jns
33. Lewis SJ & Heaton KW (1997) Increasing butyrate concentration in
the distal colon by accelerating intestinal transit. Gut 41, 245–251.
34. Soares ACF, Lederman HM, Fagundes-Neto U, et al. (2005) Breath
methane associated with slow colonic transit time in children with
chronic constipation. J Clin Gastroenterol 39, 512–515.
35. Taras D, Simmering R, Collins MD, et al. (2002) Reclassiﬁcation of
Eubacterium formicigenerans Holdeman and Moore 1974 as Dorea formici-
generans gen. nov., comb. nov., and description of Dorea longicatena sp.
nov., isolated from human faeces. Int J Syst Evol Microbiol 52, 423–428.
36. Kolida S, Meyer D & Gibson GR (2007) A double-blind placebo-
controlled study to establish the biﬁdogenic dose of inulin in
healthy humans. Eur J Clin Nutr 61, 1189–1195.
37. Tuohy KM, Kolida S, Lustenberger AM, et al. (2001) The prebiotic
effects of biscuits containing partially hydrolysed guar gum and
fructo-oligosaccharides – a human volunteer study. Br J Nutr 86,
341–348.
38. Miquel S, Martin R, Rossi O, et al. (2013) Faecalibacterium prausnitzii
and human intestinal health. Curr Opin Microbiol 16, 255–261.
39. Furet JP, Kong LC, Tap J, et al. (2010) Differential adaptation of
human gut microbiota to bariatric surgery-induced weight loss:
links with metabolic and low-grade inﬂammation markers.
Diabetes 59, 3049–3057.
40. Sokol H, Seksik P, Furet JP, et al. (2009) Low counts of
Faecalibacterium prausnitzii in colitis microbiota. Inﬂamm Bowel Dis
15, 1183–1189.
41. Lopez-Siles M, Khan TM, Duncan SH, et al. (2012) Cultured repre-
sentatives of two major phylogroups of human colonic
Faecalibacterium prausnitzii can utilize pectin, uronic acids, and
host-derived substrates for growth. Appl Environ Microbiol 78,
420–428.
42. Carnachan SM, Bootten TJ, Mishra S, et al. (2012) Effects of simu-
lated digestion in vitro on cell wall polysaccharides from kiwifruit
(Actinidia spp.). Food Chem 133, 132–139.
43. Candela M, Rampelli S, Turroni S, et al. (2012) Unbalance of intes-
tinal microbiota in atopic children. BMC Microbiol 12, 95.
44. Willing BP, Dicksved J, Halfvarson J, et al. (2010) A pyrosequen-
cing study in twins shows that gastrointestinal microbial proﬁles
vary with inﬂammatory bowel disease phenotypes. Gastroenterology
139, 1844–1854.e1.
45. Macfarlane GT & Macfarlane S (2011) Fermentation in the
human large intestine: its physiologic consequences and the
potential contribution of prebiotics. J Clin Gastroenterol 45, Suppl.,
S120–S127.
46. Millet S, Van Oeckel MJ, Aluwe M, et al. (2010) Prediction of in vivo
short-chain fatty acid production in hindgut fermenting mammals:
problems and pitfalls. Crit Rev Food Sci Nutr 50, 605–619.
47. Walker AW, Duncan SH, McWilliam Leitch EC, et al. (2005) pH
and peptide supply can radically alter bacterial populations and
short-chain fatty acid ratios within microbial communities from
the human colon. Appl Environ Microbiol 71, 3692–3700.
48. Sanchez B, Champomier-Verges MC, Collado Mdel C, et al. (2007)
Low-pH adaptation and the acid tolerance response of
Biﬁdobacterium longum biotype longum. Appl Environ Microbiol 73,
6450–6459.
10
journals.cambridge.org/jns
